Logo

Cytokinetics Receives the US FDA Acceptance of NDA for Omecamtiv Mecarbil to Treat Heart Failure with Reduced Ejection Fraction

Share this

Cytokinetics Receives the US FDA Acceptance of NDA for Omecamtiv Mecarbil to Treat Heart Failure with Reduced Ejection Fraction

Shots:

  • The NDA was based on the P-III (GALACTIC-HF) trial to evaluate omecamtiv mecarbil vs PBO in ~8000 patients with HFrEF in 35 countries across 945 sites. The US FDA has assigned the PDUFA date of Nov 30, 2022
  • The results showed a significant effect of treatment to reduce risk of the primary composite EPs of CV death or HF events while additional analyses demonstrated a greater treatment effect in patients with lower LVEF along with other characteristics & no reduction in 2EPs of time to CV death
  • In preclinical research, the therapy increased cardiac contractility without increasing intracellular myocyte calcium concentrations or myocardial oxygen consumption

Ref: Globe Newswire | Image: STAT News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions